e-SPACE Cardio-Renal-Metabolic 2022: On-demand

Published: 11 April 2022

Views:
17038
Likes:
7

Views:
17038
Likes:
7
Share:

Now Playing
Part 3 | Session 1 of 4
Welcome and Introduction
Ewa Jankowska

Up Next
8m 2s

Part 3 | Session 2 Management of iron deficiency in heart failure: new evidence, new guidelines
10m 31s

Part 3 | Session 3 Iron deficiency in chronic kidney disease: why iron matters beyond anaemia
11m 28s

Part 3 | Session 4 Interactive panel discussion

1m 29s

Part 4 | Session 1 Introduction
Vijay Chopra, Marco Metra
16m 37s

Part 4 | Session 2 2.1: The new ESC HF guidelines
8m 23s

Part 4 | Session 3 2.2: Personalised management
9m 7s

Part 4 | Session 4 2.3: Preventive cardiology
25m 36s

Part 4 | Session 5 Panel Discussion

27m 1s

Part 5 Meet the Experts: NAFLD/NASH as a metabolic disease: improving patients outcomes

1m 9s

Part 6 | Session 1 Introduction
Andrew JS Coats, Alice Cheng
8m 4s

Part 6 | Session 2 3.1: Focus on diabetology
Andrew JS Coats, Alice Cheng
9m 10s

Part 6 | Session 3 3.2: Focus on cardiology
Andrew JS Coats, Alice Cheng
7m 30s

Part 6 | Session 4 3.3: Focus on nephrology
Andrew JS Coats, Alice Cheng
33m 58s

Part 6 | Session 5 Panel Discussion
Andrew JS Coats, Alice Cheng

1m 13s

Part 7 | Session 1 Introduction
Roland E Schmieder
7m 28s

Part 7 | Session 2 The meaning of Hemoglobin A1C for the nephrologist
Roland E Schmieder
8m 10s

Part 7 | Session 3 The meaning of Hemoglobin A1C for the cardiologist
Roland E Schmieder
14m 13s

Part 7 | Session 4 Panel discussion
Roland E Schmieder

2m 6s

Part 8 | Session 1 Introduction
8m 15s

Part 8 | Session 2 4.1: GLP-1RA and CVD in diabetes
8m 15s

Part 8 | Session 3 4.2: GLP-1 RA and kidney disease in diabetes
6m 6s

Part 8 | Session 4 4.3: Obesity and cardio-metabolic disease: Role of GLP-1RA
Part 8 | Session 5 Panel discussion

1m 6s

Part 9 | Session 1 Welcome and introduction
Andrew JS Coats
5m 20s

Part 9 | Session 2 Cardio-renal-metabolic disease in a nutshell
Andrew JS Coats
6m 45s

Part 9 | Session 3 SGLT2 inhibitors in patients with type 2 diabetes and comorbidities
Andrew JS Coats
6m 42s

Part 9 | Session 4 SGLT2 inhibitors in patients with heart failure and comorbidities
Andrew JS Coats
5m 2s

Part 9 | Session 5 SGLT2 inhibitors in patients with chronic kidney disease and comorbidities
Andrew JS Coats
13m 56s

Part 9 | Session 6 Panel discussion
Andrew JS Coats

1m 39s

Part 10 | Session 1 Introduction
8m 59s

Part 10 | Session 2 5.1: Diagnosis, pathophysiology, epidemiology
10m

Part 10 | Session 3 5.2: Diabetes
8m 6s

Part 10 | Session 4 5.3: In chronic kidney disease
7m 3s

Part 10 | Session 5 5.4: Management with new drugs and devices (CCM, Intra atrial shunts and Cardiomems)
25m 14s

Part 10 | Session 6 Panel discussion

1m

Part 11 | Session 1 Introduction
Mustafa Arici, Pardeep Jhund
7m 24s

Part 11 | Session 2 Mechanism of disease interplay between CVD and CKD
Mustafa Arici, Pardeep Jhund
9m 6s

Part 11 | Session 3 The use of SGLT2is in patients with CKD and CVD with and without diabetes
Mustafa Arici, Pardeep Jhund
13m 6s

Part 11 | Session 4 Panel discussion
Mustafa Arici, Pardeep Jhund

28m 54s

Part 12 Meet the Experts: CV, mortality & kidney outcomes with GLP-1 AR in patients with T2DM
Stefan Anker

1m 15s

Part 13 | Session 1 Introduction
Fausto J Pinto, Clara Saldarriaga, Stefan Anker
8m 21s

Part 13 | Session 2 6.1: EMPEROR-Preserved
Fausto J Pinto, Clara Saldarriaga, Stefan Anker
8m 55s

Part 13 | Session 3 6.2: Preserved HF
Fausto J Pinto, Clara Saldarriaga, Stefan Anker
7m 33s

Part 13 | Session 4 6.3: Dronedarone in AF management: A 2022 update
Fausto J Pinto, Clara Saldarriaga, Stefan Anker
10m 41s

Part 13 | Session 5 6.4: Upcoming trials in 2022 (Deliver, Diamond, Iron Man)
Fausto J Pinto, Clara Saldarriaga, Stefan Anker
24m 16s

Part 13 | Session 6 Panel discussion
Fausto J Pinto, Clara Saldarriaga, Stefan Anker

36m 25s

Part 14 Meet the Experts: The HF Diabetic patient with CKD: optimizing care for a high-risk group
Silvio Inzucchi, Milton Packer

52s

Part 15 | Session 1 Introduction
Javed Butler
5m 46s

Part 15 | Session 2 The case for early identification, risk stratification and treatment of CKD
Javed Butler
5m 24s

Part 15 | Session 3 Protecting the kidney and the heart: the cardiologist's perspective
Javed Butler
6m 52s

Part 15 | Session 4 Identifying high-risk patients: the primary care physician's perspective
Javed Butler
11m 16s

Part 15 | Session 5 Panel discussion
Javed Butler

57s

Part 16 | Session 1 Welcome and introduction
Stefan Anker, Stephan Von Haehling
8m 59s

Part 16 | Session 2 8.1: Cachexia in CV disease
Stefan Anker, Stephan Von Haehling
8m 30s

Part 16 | Session 3 8.2: Cachexia in CKD
Stefan Anker, Stephan Von Haehling
8m 37s

Part 16 | Session 4 8.3: Muscle wasting in stroke
Stefan Anker, Stephan Von Haehling
31m 48s

Part 16 | Session 5 Panel discussion
Stefan Anker, Stephan Von Haehling

28m 46s

Part 17 Meet the Expert: HIF PHI: What do we know and don't know in 2022
David Wheeler

1m 44s

Part 18 | Session 1 Introduction
Giuseppe Rosano
7m 46s

Part 18 | Session 2 9.1: Diabetes and CVD today
Giuseppe Rosano
3m 53s

Part 18 | Session 3 9.2: Diabetes and kidney today
Giuseppe Rosano
7m 30s

Part 18 | Session 4 9.3: The cross-talk between kidney and heart
Giuseppe Rosano
7m 23s

Part 18 | Session 5 9.4: Therapeutic solution
Giuseppe Rosano
24m 37s

Part 18 | Session 6 Panel discussion
Giuseppe Rosano

30m 11s

Part 19 | Session 1 SGLT2 inhibition in the comorbid CKD patient
Muthiah Vaduganathan
4m 26s

Part 19 | Session 2 Panel discussion
Muthiah Vaduganathan

2m 10s

Part 20 | Session 1 Introduction
8m 29s

Part 20 | Session 2 10.1: Screening of kidney disease
8m 11s

Part 20 | Session 3 10.2: Screening of heart failure
8m 15s

Part 20 | Session 4 10.3: Horizons opened by the screening
33m 48s

Part 20 | Session 5 Panel discussion

1m 14s

Part 21 | Session 1 Welcome and introduction
Shelley Zieroth, Giuseppe Rosano
9m 27s

Part 21 | Session 2 New developments in SGLT2 inhibitor use in HFrEF and HFpEF
Shelley Zieroth, Giuseppe Rosano
9m 15s

Part 21 | Session 3 Implementing guidelines in clinical practice
Shelley Zieroth, Giuseppe Rosano
10m 43s

Part 21 | Session 4 Panel discussion
Shelley Zieroth, Giuseppe Rosano

2m 7s

Part 22 | Session 1 Introduction
Piotr Ponikowski, Muthiah Vaduganathan
8m 22s

Part 22 | Session 2 In ambulatory HFrEF and HFpEF
Piotr Ponikowski, Muthiah Vaduganathan
8m 22s

Part 22 | Session 3 When to start after acute decompensation
Piotr Ponikowski, Muthiah Vaduganathan
9m 38s

Part 22 | Session 4 Improving QoL and symptoms
Piotr Ponikowski, Muthiah Vaduganathan
2m 24s

Part 22 | Session 5 The case of acute MI
Piotr Ponikowski, Muthiah Vaduganathan
24m 22s

Part 22 | Session 6 Panel discussion
Piotr Ponikowski, Muthiah Vaduganathan

32m 8s

Part 23 Meet the Expert: The meaning of eGFR for the cardiologists and diabetologist
Kevin Damman

50s

Part 24 | Session 1 Introduction
Stefan Anker, Linda Mellbin
8m 22s

Part 24 | Session 2 Practical issues of managing weight loss in CRM disease: the therapeutic options
Stefan Anker, Linda Mellbin
8m 9s

Part 24 | Session 3 Managing weight loss in CRM disease: the nephrologist's perspective
Stefan Anker, Linda Mellbin
8m 31s

Part 24 | Session 4 Managing weight loss in CRM disease: the diabetologist's perspective
Stefan Anker, Linda Mellbin
8m 33s

Part 24 | Session 5 Managing weight loss in CRM disease: the cardiologists' perspective
Stefan Anker, Linda Mellbin
25m 47s

Part 24 | Session 6 Panel discussion
Stefan Anker, Linda Mellbin

1m 30s

Part 25 | Session 1 Welcome and introduction
Ileana L Piña, Bertram Pitt
16m 6s

Part 25 | Session 2 Overcoming barriers to guideline-mandated medical therapy in heart failure the role of long-term potassium control
Ileana L Piña, Bertram Pitt
16m 1s

Part 25 | Session 3 Interactive panel discussion
Ileana L Piña, Bertram Pitt

31m 2s

Part 26 Meet the Expert: SGLT2, the statin of the 21st century
Deepak L Bhatt

2m 39s

Part 27 | Session 1 Introduction
Hiddo Lambers Heerspink
6m 32s

Part 27 | Session 2 DAPA CKD: Key lessons from subgroup analyses
Hiddo Lambers Heerspink
6m 41s

Part 27 | Session 3 FIDELIO/FIGARO DKD
Hiddo Lambers Heerspink
8m 34s

Part 27 | Session 4 FIDELITY - Main lessons including subgroup analyses
Hiddo Lambers Heerspink
11m 1s

Part 27 | Session 5 Chlortalidone in CKD stage 4: A new look at an old drug
Hiddo Lambers Heerspink
25m 1s

Part 27 | Session 6 Panel discussion
Hiddo Lambers Heerspink

2m 1s

Part 28 | Session 1 Introduction
George L Bakris
4m 33s

Part 28 | Session 2 Screening and diagnosis best practices
George L Bakris
5m 48s

Part 28 | Session 3 Primary care perspective and challenges
George L Bakris
10m 3s

Part 28 | Session 4 Reducing CV risks and new treatment options: case discussion
George L Bakris
17m 19s

Part 28 | Session 5 Panel discussion
George L Bakris

1m 23s

Part 29 | Session 1 Introduction
Martin R Cowie, Harriette Van Spall
8m 38s

Part 29 | Session 2 Digital technologies in CV disease
Martin R Cowie, Harriette Van Spall
7m 39s

Part 29 | Session 3 Remote monitoring of HF
Martin R Cowie, Harriette Van Spall
Part 29 | Session 4 Telemedicine in CKD from a cardiologist's perspective
Martin R Cowie, Harriette Van Spall
34m 11s

Part 29 | Session 5 Panel discussion
Martin R Cowie, Harriette Van Spall

5m 21s

Part 30 | Session 1 Introduction
Stefan Anker
8m 24s

Part 30 | Session 2 Ascend D and ASCEND ND
Stefan Anker
7m 42s

Part 30 | Session 3 The moving field of drug nephrotoxicity
Stefan Anker
8m 22s

Part 30 | Session 4 The role of new potassium binding agents in cardio-renal medicine
Stefan Anker
31m 33s

Part 30 | Session 5 Panel discussion
Stefan Anker

32m 21s

Part 31 Meet the Expert: Management of worsening HF
Justin Ezekowitz, Ewa Jankowska

1m 50s

Part 32 | Session 1 Introduction
Melanie Davies, Julio Rosenstock, Nikolaus Marx
6m 50s

Part 32 | Session 2 Cardio-centric approach
Melanie Davies, Julio Rosenstock, Nikolaus Marx
9m 15s

Part 32 | Session 3 Gluco-centric approach
Melanie Davies, Julio Rosenstock, Nikolaus Marx
15m 19s

Part 32 | Session 4 Combination therapy as starting option
Melanie Davies, Julio Rosenstock, Nikolaus Marx
27m 15s

Part 32 | Session 5 Panel discussion
Melanie Davies, Julio Rosenstock, Nikolaus Marx

31m 10s

Part 1 Meet the Expert: IgA nephropathy: current optimal management Sydney Tang

55s

Part 2 | Session 1 Welcome and introduction

9m 28s

Part 2 | Session 2 1.1: BP in CKD Guidelines

8m 48s

Part 2 | Session 3 1.2: Diabetes and CKD GL

7m 30s

Part 2 | Session 4 1.3: General management of the nephrotic syndrome

31m 57s

Part 2 | Session 5 Panel Discussion

Average (ratings)

No ratings

Your rating

Overview

e-SPACE CARDIO-RENAL-METABOLIC 2022, held on 4-6 March 2022, was the second edition of the global online conference on cardio renal metabolic diseases.

The organisers, under the direction of a world-renowned scientific committee, brought together leading experts in cardiology, nephrology, and diabetology to share clinical practice strategies in treating the inter-related diseases now affecting hundreds of millions people worldwide.

This on-demand version of the event comprises:

Presentations and discussions with leading experts
Evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease & obesity
Insight to SLGT2i, GLP-1RA and other emerging therapies
'Meet the Expert' sessions

e-SPACE Cardio-Renal-Metabolic 2022 was supported by the following companies:

More from this programme

Part 1

Meet the Expert: IgA nephropathy: current optimal management

1 session
Meet the Expert: IgA nephropathy: current optimal management	Watch now

Part 2

Session 1: The new KDIGO guidelines

5 sessions
Welcome and introduction	Watch now
1.1: BP in CKD Guidelines	Watch now
1.2: Diabetes and CKD GL	Watch now
1.3: General management of the nephrotic syndrome	Watch now
Panel Discussion	Watch now

Part 3

Industry Session: Iron deficiency in heart failure and kidney disease: interdisciplinary crosstalk

Supported by an unrestricted educational grant from Vifor Pharma

4 sessions
Welcome and Introduction	Watch now
Management of iron deficiency in heart failure: new evidence, new guidelines	Watch now
Iron deficiency in chronic kidney disease: why iron matters beyond anaemia	Watch now
Interactive panel discussion	Watch now

Part 4

Session 2: Recent CV guidelines and treatment algorithms

5 sessions
Introduction	Watch now
2.1: The new ESC HF guidelines	Watch now
2.2: Personalised management	Watch now
2.3: Preventive cardiology	Watch now
Panel Discussion	Watch now

Part 5

Meet the Experts: NAFLD/NASH as a metabolic disease: improving patients outcomes

1 session
Meet the Experts: NAFLD/NASH as a metabolic disease: improving patients outcomes	Watch now

Part 6

Session 3: Management of SGLT2 a practical approach

5 sessions
Introduction	Watch now
3.1: Focus on diabetology	Watch now
3.2: Focus on cardiology	Watch now
3.3: Focus on nephrology	Watch now
Panel Discussion	Watch now

Part 7

Meet the Experts: The meaning of Hemoglobin A1C for the nephrologist and the cardiologist

4 sessions
Introduction	Watch now
The meaning of Hemoglobin A1C for the nephrologist	Watch now
The meaning of Hemoglobin A1C for the cardiologist	Watch now
Panel discussion	Watch now

Part 8

Session 4: GLP-1RA and cardio-metabolic disease in diabetes

5 sessions
Introduction	Watch now
4.1: GLP-1RA and CVD in diabetes	Watch now
4.2: GLP-1 RA and kidney disease in diabetes	Watch now
4.3: Obesity and cardio-metabolic disease: Role of GLP-1RA	Watch now
Panel discussion	Watch now

Part 9

Industry Session: SGLT2 inhibitors in cardio-renal-metabolic disease: optimizing the patient's journey

Supported by an independent educational grant from Boehringer Ingelheim & Eli Lilly Alliance

6 sessions
Welcome and introduction	Watch now
Cardio-renal-metabolic disease in a nutshell	Watch now
SGLT2 inhibitors in patients with type 2 diabetes and comorbidities	Watch now
SGLT2 inhibitors in patients with heart failure and comorbidities	Watch now
SGLT2 inhibitors in patients with chronic kidney disease and comorbidities	Watch now
Panel discussion	Watch now

Part 10

Session 5: HFpEF: tackling a multidisciplinary problem

6 sessions
Introduction	Watch now
5.1: Diagnosis, pathophysiology, epidemiology	Watch now
5.2: Diabetes	Watch now
5.3: In chronic kidney disease	Watch now
5.4: Management with new drugs and devices (CCM, Intra atrial shunts and Cardiomems)	Watch now
Panel discussion	Watch now

Part 11

Meet the Experts: CKD progression in CVD screening and follow-up

4 sessions
Introduction	Watch now
Mechanism of disease interplay between CVD and CKD	Watch now
The use of SGLT2is in patients with CKD and CVD with and without diabetes	Watch now
Panel discussion	Watch now

Part 12

Meet the Experts: CV, mortality & kidney outcomes with GLP-1 AR in patients with T2DM

1 session
Meet the Experts: CV, mortality & kidney outcomes with GLP-1 AR in patients with T2DM	Watch now

Part 13

Session 6: New trial update in cardiology

6 sessions
Introduction	Watch now
6.1: EMPEROR-Preserved	Watch now
6.2: Preserved HF	Watch now
6.3: Dronedarone in AF management: A 2022 update	Watch now
6.4: Upcoming trials in 2022 (Deliver, Diamond, Iron Man)	Watch now
Panel discussion	Watch now

Part 14

Meet the Experts: The HF Diabetic patient with CKD: optimizing care for a high-risk group

1 session
Meet the Experts: The HF Diabetic patient with CKD: optimizing care for a high-risk group	Watch now

Part 15

Meet the Expert: Multidisciplinary management of cardio-renal-metabolic disease: focus on the kidney

5 sessions
Introduction	Watch now
The case for early identification, risk stratification and treatment of CKD	Watch now
Protecting the kidney and the heart: the cardiologist's perspective	Watch now
Identifying high-risk patients: the primary care physician's perspective	Watch now
Panel discussion	Watch now

Part 16

Session 8: Sarcopenia, frailty malnutrition and cachexia

5 sessions
Welcome and introduction	Watch now
8.1: Cachexia in CV disease	Watch now
8.2: Cachexia in CKD	Watch now
8.3: Muscle wasting in stroke	Watch now
Panel discussion	Watch now

Part 17

Meet the Expert: HIF PHI: What do we know and don't know in 2022

1 session
Meet the Expert: HIF PHI: What do we know and don't know in 2022	Watch now

Part 18

Session 9: The cardio-kidney interaction: relevance to diabetes

6 sessions
Introduction	Watch now
9.1: Diabetes and CVD today	Watch now
9.2: Diabetes and kidney today	Watch now
9.3: The cross-talk between kidney and heart	Watch now
9.4: Therapeutic solution	Watch now
Panel discussion	Watch now

Part 19

Industry Session: SGLT2 inhibition in the comorbid CKD patient

Satellite Symposium supported by an unrestricted educational grant from AstraZeneca

2 sessions
SGLT2 inhibition in the comorbid CKD patient	Watch now
Panel discussion	Watch now

Part 20

Session 10: Why and how to screen for heart failure and kidney disease in diabetes

5 sessions
Introduction	Watch now
10.1: Screening of kidney disease	Watch now
10.2: Screening of heart failure	Watch now
10.3: Horizons opened by the screening	Watch now
Panel discussion	Watch now

Part 21

Meet the Expert: SGLT2 inhibitors in heart failure: Improving outcomes across the spectrum of the disease

4 sessions
Welcome and introduction	Watch now
New developments in SGLT2 inhibitor use in HFrEF and HFpEF	Watch now
Implementing guidelines in clinical practice	Watch now
Panel discussion	Watch now

Part 22

Session 11: SGLT2 inhibition in clinical practice

6 sessions
Introduction	Watch now
In ambulatory HFrEF and HFpEF	Watch now
When to start after acute decompensation	Watch now
Improving QoL and symptoms	Watch now
The case of acute MI	Watch now
Panel discussion	Watch now

Part 23

Meet the Expert: The meaning of eGFR for the cardiologists and diabetologist

1 session
Meet the Expert: The meaning of eGFR for the cardiologists and diabetologist	Watch now

Part 24

Session 12: Managing obesity in the CRM setting

6 sessions
Introduction	Watch now
Practical issues of managing weight loss in CRM disease: the therapeutic options	Watch now
Managing weight loss in CRM disease: the nephrologist's perspective	Watch now
Managing weight loss in CRM disease: the diabetologist's perspective	Watch now
Managing weight loss in CRM disease: the cardiologists' perspective	Watch now
Panel discussion	Watch now

Part 25

Meet the Experts: Personalized care of patients with heart failure: hyperkalemia as a barrier to optimal medical therapy

3 sessions
Welcome and introduction	Watch now
Overcoming barriers to guideline-mandated medical therapy in heart failure the role of long-term potassium control	Watch now
Interactive panel discussion	Watch now

Part 26

Meet the Expert: SGLT2, the statin of the 21st century

1 session
Meet the Expert: SGLT2, the statin of the 21st century	Watch now

Part 27

Session 13: New trial update in nephrology

6 sessions
Introduction	Watch now
DAPA CKD: Key lessons from subgroup analyses	Watch now
FIDELIO/FIGARO DKD	Watch now
FIDELITY - Main lessons including subgroup analyses	Watch now
Chlortalidone in CKD stage 4: A new look at an old drug	Watch now
Panel discussion	Watch now

Part 28

Meet the Experts: Reducing the risk of cardiovascular events for patients with CKD and T2DM: new treatment options

5 sessions
Introduction	Watch now
Screening and diagnosis best practices	Watch now
Primary care perspective and challenges	Watch now
Reducing CV risks and new treatment options: case discussion	Watch now
Panel discussion	Watch now

Part 29

Session 14: Telemedicine in CRM

5 sessions
Introduction	Watch now
Digital technologies in CV disease	Watch now
Remote monitoring of HF	Watch now
Telemedicine in CKD from a cardiologist's perspective	Watch now
Panel discussion	Watch now

Part 30

Session 15: New drugs, new hopes and sometimes risks

5 sessions
Introduction	Watch now
Ascend D and ASCEND ND	Watch now
The moving field of drug nephrotoxicity	Watch now
The role of new potassium binding agents in cardio-renal medicine	Watch now
Panel discussion	Watch now

Part 31

Meet the Expert: Management of worsening HF

1 session
Meet the Expert: Management of worsening HF	Watch now

Part 32

Session 16: Harmonising the gluco-and cardio-centric management of diabetes

5 sessions
Introduction	Watch now
Cardio-centric approach	Watch now
Gluco-centric approach	Watch now
Combination therapy as starting option	Watch now
Panel discussion	Watch now

Faculty Biographies

Ewa Jankowska

Prof Ewa Jankowska is Professor of Medicine and Head of Laboratory of Applied Research on Cardiovascular System at the Department of Heart Diseases, Wroclaw Medical University, Poland. Her clinical and research interests include the role of peripheral mechanisms in the progression of heart failure, co-morbidities in heart failure, and experimental model of tachycardia-induced cardiomyopathy.

Prof Jankowska is an Editorial Board member of Cardiac Failure Review.

View full profile